Objective-Notch signaling has been implicated in the development of pulmonary arterial hypertension (PH) as reflected by increased expression of Notch member proteins that induce the proliferation of pulmonary arterial smooth muscle cells (PASMCs). Soluble Jagged1 (sJag1) has been shown to inhibit Notch signaling in vitro and in vivo; however, its capacity to suppress PH remains unknown. Approach and Results-Notch1, Notch3, Jagged1, and Herp2 protein were highly expressed in both the mouse model of hypoxia-induced PH and the rat model of monocrotaline-induced PH. By attenuation and reversal of multiple pathological processes that were associated with PH, adenoviral sJag1 transfection significantly reduced the proliferation and enhanced the apoptosis of PASMCs in PH, whereas vehicle had no effect. The sJag1 inhibitory effect on Notch activation is likely related to its interference with ligand-induced signaling. Importantly, the administration with adenoviral sJag1 improved the survival rate of PH rats. Furthermore, sJag1 can restore the PH-PASMCs phenotype from the dedifferentiated to the differentiated state, by giving a positive effect on the physical binding of myocardin to the CC(A/T) n GG (CArG)containing regions of vascular smooth muscle cells-specific promoters. Conclusions-Our results demonstrated that the potential therapeutic use of the sJag1 may not only inhibit the proliferation of PASMCs but also restore the PH-PASMCs phenotype from the dedifferentiated to the differentiated state through interference with Notch-Herp2 signaling. (Arterioscler Thromb Vasc Biol. 2013;33:2733-2739 .) The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
P ulmonary hypertension (PH) is a progressive disease of various origins that is associated with increased pulmonary vascular resistance and results in right ventricular hypertrophy and eventual right heart dysfunction. 1 Structural remodeling of small pulmonary arteries and arterioles is progressive and diffuse change that causes vessel wall thickening and obliteration of the distal pulmonary arterial tree mostly by excessive proliferation of pulmonary arterial smooth muscle cells (PASMCs). 2, 3 Furthermore, PH-PASMCs, similar to other adult vascular smooth muscle cells (vSMCs), are highly plastic and capable of modulating their phenotype in response to exogenous stimuli, cell-to-cell interaction, and cell-to-matrix signaling. 4 And the transition from the contractile phenotype of normal PASMCs to proproliferative and antiapoptotic phenotype of PH-PASMCs is a key pathologically responsible for all kinds of PH. 5 Importantly, the unique phenotype of PASMCs remains duratively unchanged, even if isolated from a patient with PH or a PH animal model. 6 However, the mechanism of how the genetic pathway regulates plasticity and proliferation of PASMCs remains unknown.
The Notch signaling is an evolutionarily conserved regulatory system that plays a prominent role in cell fate decisions including proliferation, differentiation, and survival. 7 The effect of Notch signaling is based on the expression of certain genes in a cell-type-specific manner. 8 Notch protein members are expressed on the surface of the cell that is activated by Notch receptors (Notch1, -2, -3, -4) interacting with ligands (Jagged1, -2, and delta-like [Dll]-1, -3, -4). Among the Notch receptors, only Notch1, 2, and 3 are expressed on vasculature and critical in regulation of vascular morphogenesis and function during development and disease. 9 Ligand binding triggers a conformational change in proteolytic cleavage of the receptor by the presenilin-γ-secretase complex and release of the intracellular domain of Notch, which translocates into the nucleus and interacts with the DNA-binding protein, endogenous Cp-binding factor-1 (also termed CSL or recombination signal sequence-binding protein-J kappa). This transcriptional activator complex induces transcription of target genes, most notably the Hey and Herp genes, which regulate cell fate. 10 Recently, the Notch signal pathway has been demonstrated to be involved in the development of PH associated with PASMC proliferation. 11 Overexpression of Notch1 increased proliferation and inhibited apoptosis of vSMCs. 12 Furthermore, members of the Notch family can have been fundamentally extended to regulate vSMC plasticity. 13 Consistently, Jagged1 increased the expression of smooth muscle-myosin heavy chain, whereas the Notch downstream transcription factors HES-related repressor December 2013 protein (HERP) 1 and HERP2 were able to stimulate vSMC proliferation and differentiation. 14, 15 Because proliferation of PASMCs is a prerequisite for all kinds of PH, we hypothesized that blockage of Notch signaling could inhibit formation and development of PH. Soluble Jagged1 (sJag1) has been shown to inhibit Notch signaling in vitro and in vivo 16, 17 ; however, its capacity to suppress PH remains unknown. Here, we showed that 2 kinds of rodent PH models, including the hypoxia-induced mouse and the monocrotaline (MCT)-induced rat, were inhibited by administration of sJag1 treatment. Accordingly, sJag1 was able to reduce the PASMCs proliferation and restore the phenotype by interfering with Notch signaling involving depression of Herp2 expression.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Notch/Jagged1 Signaling Was Highly Activated in PH
To investigate the expression pattern of Notch signaling pathway in normal and PH lungs, we studied 2 kinds of PH rodent models including hypoxia-induced mouse and MTC-induced rat. The Verhoeff-Van Gieson stain sections for lung tissue clearly showed that there was significantly increased vascular medial thickening in the PH models of rat ( Figure 1A ) and mouse. Consistent with this observation, our studies showed that the mean pulmonary arterial pressures (mPAP) by day 35 in hypoxia-mouse and by day 42 in MTC-rat were significantly higher than those in normal ( Figure 2B ). Collectively, it was suggested that PH has been successfully induced in the hypoxia-treated mouse and MTC-treated rat.
Next, we isolated PASMCs from normotensive lung in mouse and rat and PH-PASMCs from hypoxia-induced mice and MTC-induced rat. Western blot data showed that these PH-PASMCs in rat and mouse exhibited a higher protein expression level on Notch1, Notch3, and Jagged1 than those PASMCs in normotensive lung ( Figure 1C ). However, we found no difference in Dll1 protein level between normal and PH in both rat and mouse. These results demonstrated that there was a direct involvement of Notch1, Notch3, and Jagged1 in the development of PH ( Figure 1D and 1E) .
To test whether the protein expression of Notch1, Notch3, and Jagged1 correlated with the progression of PH, we studied PASMCs of rat model at serial time points during development of PH. Western blot showed that there was progressively increased expression of Notch1, Notch3, and Jagged1 protein in rat as time went on since the initiation of MCT treatment ( Figure 1F and 1G ). Furthermore, high expression level of Jagged1 protein in lung tissue of rat-PH model was correlated with worsening disease severity ( Figure 1H ). In contrast to Jagged1, we found no difference in the expression of Dll1 protein in the normotensive lung compared with that of PH rat. Taken together, our results indicated that expression levels of Notch1, Notch3, and Jagged1 proteins correlated with the severity of PH in the rodent models.
sJag1 Ameliorated the Development of PH
To determine the effect of Jagged1 on the development of PH, we examined the therapeutic potential of sJag1 with adenoviral vector (Ad-sJag1) through interference Notch receptor (including Notch1 and Notch3) to interact with Jagged1. Our experiment first tested the effect of Ad-sJag1 administration on rat-PH model since day 0 after MCT treatment. Morphometric analysis was performed on lung tissue cross-section by 0 and 42 days after MCT-treated rats that were instilled with Ad-sJag1 or vehicle ( Figure 2A ). We observed that there was significant PH established by day 21 in rats that received vehicle but not those that received Ad-sJag1. Although mPAP increased further between days 21 and 42 in all MCT-treated rats, the level of mPAP on day 42 in Ad-sJag1-treated rats was significantly lower than that in vehicle treatment ( Figure 2B ). In contrast, our results showed that there was no change in systemic blood pressure in all animals ( Figure 2C ). Consistent with this observation, the rats that received vehicle exhibited more increased vascular medial thickening ( Figure 2D ) and right ventricular hypertrophy ( Figure 2E ) than those that received Ad-sJag1. Furthermore, the death rate corresponded to those observations of morphometric analysis, and Ad-sJag1 improved the survival rate of PH rats ( Figure 2F ). Together, these findings indicated that Ad-sJag1 can interfere with Notch receptors interacting with Jagged1 and inhibit the formation of PH.
Next, we evaluated the therapeutic potential of sJag1 at a time point when PH pathology had already been established. The administration of Ad-Jag1 on day 21 after MCT treatment did not completely reverse but did halt the progression of PH, as judged on measurement of mPAP ( Figure 2G ), right ventricular hypertrophy ( Figure 2H ), and pulmonary arterial wall thickness ( Figure 2I ) on day 42 after MCT treatment. Taken together, those results demonstrated that sJag1 can interfere with Notch receptors interacting with Jagged1 and inhibit the development of PH.
sJag1 Attenuated the Proliferative Properties of PH-PASMCs
Because excessive proliferation of PH-PASMCs was the major underlying mechanism of vascular structure remodeling in the PH, we examined whether Ad-sJag1 can downregulate the proliferative properties of PH-PASMCs. Four sets of experiments were performed. First, using intracellular staining with proliferating cell nuclear antigen, we evaluated the effect of Ad-sJag1 on PH-PASMCs proliferation in vivo. Expression of proliferating cell nuclear antigen was significantly higher in PH rats that receive vehicle treatment as compared with normal pulmonary arterial wall, whereas Ad-sJag1 drastically reduced proliferating cell nuclear antigen-positive PH-PASMCs nearly to a basal level ( Figure 3A ). This indirectly reflected Figure 3B ). Third, we isolated PH-PASMCs from MCT-induced rats with Ad-sJag1 and vehicle treatment. Western blot showed that Ad-sJag1treated lung exhibited a high expression level of Jagged1 protein in PASMCs, whereas nil to minimal level of Jagged1 protein expression was found in lung tissue that received vehicle treatment ( Figure 3C ). Western blot data were reflected by the reverse transcription polymerase chain reaction data revealing that Ad-sJag1-treated lung expressed approximately twice more Jagged1 mRNA compared with vehicle-treated lung ( Figure 3D ). Finally, the direct evidence for the inhibitory activity of Ad-sJag1 on PH-PASMC proliferation was obtained from a cell subculture experiment. Our studies showed that subculture PH-PASMCs from Ad-sJag1-treated lung had roughly half the proliferative rate as that of PH-PASMCs from vehicle-treated lung ( Figure 3E ). Collectively, these experiments indicated that Ad-sJag1 not only attenuates the proproliferative properties of PH-PASMCs but also induces apoptosis. 
Jagged1 Mediated Phenotype of PASMCs Dependent on Notch Signaling
Because the administration of Ad-sJag1 can inhibit PH, we examined how the effect of Ad-sJag1 on the proliferation of PASMCs was dependent on Notch signaling. As shown in Figure 4A , Western blotting revealed that Ad-sJag1 inhibited the expression of Herp2 protein. To gain a better understanding of molecular pathways involved in Notch-Herp2 signaling, we first compared phenotypic pattern of PASMCs from normal lung, PH-lung, and PH-lung treated with Ad-sJag1.
In PH-PASMCs, expression of proteins associated with differentiated/contractile phenotype, including SM 22α and smooth muscle major heavy chain, were decreased in comparison with the PASMCs of normal lung and PH-PASMCs treated with Ad-sJag1 ( Figure 4B ). In contrast, the PASMCs dedifferentiated, or the synthetic-specific marker proteins, including syndecan-1, were more abundant in PH-PASMCs than that in normal and Ad-sJag1-treated PH-PASMCs ( Figure 4B ). The next studies were to show how Ad-sJag1 signaling can restore PASMCs differentiation. We studied myocardin expression by Western blotting and demonstrated that Ad-sJag1 upregulated myocardin protein expression in PH-PASMCs ( Figure 4C) . Given the effect of Ad-sJag1 on myocardin, we then tested whether physical binding of myocardin to the CArG-containing regions of PASMCs-specific promoters was indeed affected. Using quantitative chromatin immunoprecipitation assays, we found a lower level of myocardin binding to the CArG-containing regions of smooth muscle 22 and SM MHC promoters in PH-PASMCs as compared with that of normal and Ad-sJag1-treated PH-PASMCs ( Figure 4D and 4E) . The observed effects of Ad-sJag1 on PASMC-specific transcription may explain Notch signalingdependent reverse modulation of PH-PASMC phenotype from the dedifferentiated to the differentiated state.
Discussion
In this study, we demonstrated that sJag1 effectively attenuates mPAP and pulmonary vascular resistance through attenuation of Notch signaling and subsequent reduction of PASMC proliferation on PH. To our knowledge, this is the first demonstration that Jagged1 pathway is activated in the development of PH. Importantly, we provide intriguing evidence that the pathological antiapoptotic and proliferative PASMC phenotype is reversed toward the normal PASMCs phenotype by the administration of Ad-Jag1. The most important character in PH is pulmonary vascular remodeling that consists of the thickening of the vascular intima and media and generally thought to result from cell hypertrophy, proliferation, migration, and extracellular matrix deposition. [18] [19] [20] This process involves many cell types, including endothelial cells, smooth muscle cells, fibroblasts, inflammatory cells, and platelets. 21, 22 To assess whether Notch signaling may regulate proliferation of PASMCs, we examined the protein expression during the development of PH. Our studied demonstrated that this process is associated with an increased expression of Notch1, Notch3, and Jagged1 in both the mouse model of hypoxia-induced PH and the rat model of MCT-induced PH. Since the start of MCT induction on the rat-PH model, there is an obvious and gradient upregulation of Notch1 and Jagged1 in the pulmonary arterial wall, indicating a quick induction of Notch signal pathway expression and activation in the formation of PH. In agreement with previously published data, the upregulation of Notch members, such as Notch1, can induce the proliferation of PASMCs. 2, 23 However, the pathway by which notch signal regulates the proliferation of PASMCs remains unknown. Especially, the notch ligands Dll1 and Jagged1 have totally opposing effects, and Jagged1 is a critical positive regulator because of its ability to modulate Notch/Dlll signaling. 24 Our studies showed that it was Jagged1 but not Dll1 that highly expresses in PH-PASMCs. After binding with ligand Jagged1, notch1 triggers proteolytic cleavage and release of intracellular domain of Notch, which increase the downstream Herp2 and interacts with the DNA-binding protein. To our knowledge, this is first demonstration that Notch1/Jagged1 signal pathway is critical for proliferation of PH-PASMCs. Importantly, we provide intriguing evidence that the formation and development of pulmonary arterial hypertension can be inhibited by blocking Notch1/Jagged1 signal pathway. The ligand is cleaved on receptor interaction by the same proteases, giving rise to a soluble extracellular ligand domain that can influence notch signal as well. 25 Notch ligands induce signaling only when expressed as immobilized forms, whereas they show no activity or antagonistic activity when as soluble forms. The free as well as immobilized Jagged1 promotes proliferation of PASMCs to induce PH. In contrast, sJag1 influences Notch ligand-binding results toward inhibition of downstream signaling. For example, the free sJag1 has a dominant negative effect on stem cell and macrophage progenitors. 16, 17 In line with these previous studies, our results also showed that sJag1 inhibits proliferation of PA-PASMCs and attenuated pulmonary arterial pressure and pulmonary vascular resistance. Moreover, these results suggest potential clinical use of recombinant Notch ligand, sJag1, for inhibiting proliferation PASMCs in vivo and in vitro.
Our studies also revealed that sJag1 can inhibit Notch downstream signaling, the expression of Herp2 in the development of PH. This finding may be significant because of a recent study that Ad-sJag1 infection in vitro reduced Herp2 mRNA expression in vSMCs, suggesting an inhibitory effect on Notch/Jagged1 signaling. 26 From in vitro and in vivo studies, it has been demonstrated that Herp2, as downstream of the Notch/Jagged1 signaling, regulates vSMCs differentiation and migration, and induces vascular remodeling in response to stimuli. 10, 27 Furthermore, the observation that the hampered proliferation of the Ad-sJag-treated vSMCs could be partially rescued by Herp2 overexpression suggests that Notch-Herp2 signaling is required for vSMCs function, and that sJag1 is an inhibitor for notch signaling both in vivo and in vitro. 22, 28 The unique PH-PASMC phenotype is important for the development of PH. 5 Notch signaling has been reported to promote vSMCs differentiation by enhancing myocardin/serum response factor binding to CArG box. 15, 29 And sJag1 can reduce Notch signal member expression concomitant with vSMC (Ad-sJaged1) . B, Western blot analysis of protein of smooth muscle 22 (SM22), smooth muscle major heavy chain (SM MHC), and syndecan-1 in normal PASMCs, PH-PASMCs treated with vehicle, and PH-PASMCs treated with Ad-sJaged1. C, Western blot analysis of protein of myocardin in normal PASMCs, PH-PASMCs treated with vehicle, and PH-PASMCs treated with Ad-sJaged1. In separate studies, these cells were processed for chromatin immunoprecipitation assays, and reverse transcription polymerase chain reaction was performed on immunoprecipitants using primers for the CArG containing regions of SM22-(D) and SM MHC-(E) specific promoters. Data are means±SEM. marker α smooth muscle actin expression in neointima formation of a rat carotid artery injury model. 30 In line with these studies, our study provides a clear demonstration that sJag1 gives a positive effect on the physical binding of myocardin to the CArG-containing regions of vSMCs-specific promoters, such as smooth muscle 22 and smooth muscle major heavy chain.
In summary, our work provides an intriguing therapeutic strategy for attenuation and reversal of multiple pathological processes that are associated with PH in the hypoxia-induced mouse model and the MCT-induced rat model by interfering with Notch-Herp2 signaling. The sJag1 inhibitory effect on Notch activation is likely related to its interference with ligand-induced signaling. Additionally, the potential therapeutic use of the sJag1 may not only inhibit the proliferation of PASMCs but also restore the PH-PASMC phenotype from the dedifferentiated to the differentiated state.
